HSP90 inhibitor, STA9090 demonstrated preclinical anti-tumorigenicity by disrupting the association of HSP90 with its co-chaperone p23 in in vitro and in vivo models of non-small cell lung cancer,34 and by degrading the key HSP90 clients such as AKT and other receptor tyrosine kinases in pheochromocytoma35. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.